<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30092">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889017</url>
  </required_header>
  <id_info>
    <org_study_id>V 1.0 22/05/2013</org_study_id>
    <nct_id>NCT01889017</nct_id>
  </id_info>
  <brief_title>Generic Immunosuppressive Drugs After Lung Transplantation</brief_title>
  <official_title>Generic Immunosuppressive Drugs After Lung Transplantation - a Crosssectional Observational Study by Patient Questionnaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extent of use of generics immunosuppressive drugs in clinical practice after lung
      transplantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Solid organ transplant recipients are treated with immunosuppressive drugs to prevent
      rejection of their grafts. The most frequently important maintenance immunosuppressive drugs
      in Europe are calcineurin inhibitors.

      For a number of these compounds drug patents have expired in recent years and generic
      formulations have entered the market. There is considerable debate regarding the efficacy
      and safety of generic drug substitution in solid organ recipients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Frequency of use of generic immunosuppressive drugs</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcineurin inhibitor through levels</measure>
    <time_frame>baseline, retrospective 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency of calcineurin inhibitor through levels in target range between generic and original immunosuppressive drugs during last 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of calcineurin inhibitors</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dose of calcineurin inhibitors between generic and original immunosuppressive drugs at questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy adherence</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Therapy adherence between generic and original immunosuppressive drugs. Adherence will be measured by a 5 item Likert scale covering self-monitoring, generla health perception, contacts, nutrition/exercise compliance and adherence to immunosuppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with immunosuppression</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Satisfaction with immunosuppression between generic and original immunosuppressive drugs will be measured by a 5-point Likert scale.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Immunosuppressive After Lung Transplantation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patient questionnaire (tablet pc based)</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients after lung transplantation (single, double or combined) with an immunosuppressive
        therapy with tacrolimus or ciclosporin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients after lung transplantation (single, double or combined)

          -  informed consent

          -  patient with an immunosuppressive therapy with tacrolimus or ciclosporin

        Exclusion Criteria:

          -  immunosuppressive therapy without calcineurin inhibitors

          -  need for isolation (Colonization with multi. or pan resistant organisms e.g.
             methicillin-resistant staph. aureus[MRSA), B. cenocepacia)

          -  limited German language skills or other reasons which might impair patient
             communication or computer handling
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jens Gottlieb, MD</last_name>
    <phone>0049511-532</phone>
    <phone_ext>4601</phone_ext>
    <email>gottlieb.jens@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imke Zinowsky</last_name>
    <phone>0049511-532</phone>
    <phone_ext>5841</phone_ext>
    <email>zinowsky.imke@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hanover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imke Zinowsky</last_name>
      <phone>0049-5115325841</phone>
    </contact>
    <investigator>
      <last_name>Jens Gottlieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Greer, MB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Ringshausen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 15, 2013</lastchanged_date>
  <firstreceived_date>June 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Thomas Fuehner</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>generic immunosuppressive</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
